EMERYVILLE, Calif., Nov. 12 Bionovo, Inc.(Nasdaq: BNVI) announced today the appointment of Ethan Weiss, M.D., to thecompany's Scientific Advisory Board. Dr. Weiss is a cardiologist withexpertise in clotting and coagulation diseases, and is a leading researcher atthe Cardiovascular Research Institute and the Division of Cardiology at theUniversity of California, San Francisco (UCSF).
"We are very excited to have Ethan on the scientific advisory board as weare advancing our drugs," said Isaac Cohen, O.M.D., Bionovo's Chairman andCEO. He added, "Dr. Weiss's research focuses on the mechanism of clottingactivation by estrogens. His work is critical to the clotting safetyelucidation of Bionovo's estrogen receptor beta selective drugs."
Dr. Weiss added, "Our results, so far, are very comforting. In earlyexperiments we can see that in contrast to estrogen, MF101 has no effect onclotting. Therefore, MF101 will most likely be a safer alternative for thetreatment of menopausal symptoms."
Dr. Ethan Weiss joined the faculty at UCSF in 2003 as Assistant Professorof Medicine. Dr. Weiss earned his medical degree from the Johns HopkinsUniversity School of Medicine, and he completed his internship and residencyat the John Hopkins Hospital. Dr. Weiss came to the University of California,San Francisco in 1998 as a cardiology fellow where he spent three years underthe scientific mentorship of Dr. Shaun Coughlin in the Cardiovascular ResearchInstitute studying the effects of thrombin signaling in platelets. He thencompleted his clinical fellowship and served as Chief Cardiology Fellow in2002. Dr Weiss' clinical focus includes acute care cardiology, coronary arterydisease and general cardiology with special interests in thrombosis,preventive cardiology, and acute coronary syndromes. Dr. Weiss' laboratoryuses forward genetic models to enhance the understanding of mechanisms ofhemostasis and thrombosis. In addition, his group is working to understandmechanisms of sex differences in blood clotting and to define the mechanismswhereby estrogen increases the risk of clotting.
Bionovo is a pharmaceutical company focused on the discovery anddevelopment of safe and effective treatments for women's health and cancer,markets with significant unmet needs and billions in potential annual revenue.The company applies its expertise in the biology of menopause and cancer todesign new drugs derived from botanical sources which have novel mechanisms ofaction. Based on the results of early and mid-stage clinical trials, Bionovobelieves they have discovered new classes of drug candidates within their richpipeline with the potential to be leaders in their markets. Bionovo isheadquartered in Emeryville, California and is traded on the NASDAQ CapitalMarket under the symbol, "BNVI". For more information about Bionovo and itsprograms, visit: http://www.bionovo.com.
Forward Looking Statements
This release contains certain forward-looking statements relating to thebusiness of Bionovo, Inc. that can be identified by the use of forward-lookingterminology such as "believes," "expects," or similar expressions. Suchforward-looking statements involve known and unknown risks and uncertainties,including uncertainties relating to product development, efficacy and safety,regulatory actions or delays, the ability to obtain or maintain patent orother proprietary intellectual property protection, market acceptance,physician acceptance, third party reimbursement, future capital requirements,competition in general and other factors that may cause actual results to bematerially different from those described herein as anticipated, believed,estimated or expected. Certain of these risks and uncertainties are or will bedescribed in greater detail in our filings with the Securities and ExchangeCommission, which are available at http://www.sec.gov. Bionovo, Inc. is underno obligation (and expressly disclaims any such obligation) to update or alterits forward-looking statements whether as a result of new information, futureevents or otherwise.
SOURCE Bionovo, Inc.